|
|
| | 1-((2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxyMethyl)-3-Methyltetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione Basic information |
| Product Name: | 1-((2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxyMethyl)-3-Methyltetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione | | Synonyms: | 1-((2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxyMethyl)-3-Methyltetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione;Sofosbuvir metabolites GS331007;1-(2-C-Methyl-β-D-arabinofuranosyl)-2,4(1H,3H)-pyrimidinedione;1-(2'-C-methyl-β-D-arabinofuranosyl)uracil;Hydroxyuridine/Sofosbuvir Impurity 12;2,4(1H,3H)-Pyrimidinedione, 1-(2-C-methyl-β-D-arabinofuranosyl)-;Sofosbuvir Methylarabinosyl Impurity;1-β-D-Arabinofuranosyluracil-2-C-methyl | | CAS: | 114262-49-6 | | MF: | C10H14N2O6 | | MW: | 258.23 | | EINECS: | | | Product Categories: | | | Mol File: | 114262-49-6.mol |  |
| | 1-((2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxyMethyl)-3-Methyltetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione Chemical Properties |
| Melting point | 132-135 °C | | density | 1.572±0.06 g/cm3(Predicted) | | pka | 9.39±0.10(Predicted) |
| | 1-((2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxyMethyl)-3-Methyltetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione Usage And Synthesis |
| Uses | 1-β-D-Arabinofuranosyluracil-2-C-methyl is an impurity of PSI-7977 (P839640), a prodrug that is metabolized to the active antiviral agent 2''-deoxy-2''-α-fluoro-β-C-methyluridine-5''-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled PSI-7977 as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase. |
| | 1-((2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxyMethyl)-3-Methyltetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione Preparation Products And Raw materials |
|